Researchers at VCU Massey Comprehensive Cancer Center have developed a novel algorithm that could provide a revolutionary ...

The firm is developing the PHOX2B-targeted cell therapy, which has shown promise in preclinical xenograft models, with CHOP researchers.

A new platform comprehensively profiles CAR T-cells during manufacturing, revealing phenotypic shifts. This allows for ...

In modern immunotherapy, modified immune cells are introduced into the body to attack tumors and other targets.

The cure to cancer may not be hidden in some drug or chemical but within our own body. A team of Chinese researchers recently ...

Analysts at Truist Securities called J&J’s CAR-T readout “compelling,” noting that the efficacy figures could position the ...

T cells are a promising cancer therapy that are made from the patient's own T cells, which are reprogrammed to fight their ...

bNational Institute of Health and Care Research (NIHR) Blood and Transplant Research Unit (BTRU) in Precision Cellular Therapeutics, University of Birmingham, Birmingham, UK cNIHR Biomedical Research ...

Cytotoxicity assays using anti-PNE CAR-T cells and different concentrations of PNE-tagged HER2 Fab switches were performed using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega) based on ...

CAR T-cell therapies offer high response rates but face logistical challenges, including lengthy "brain-to-vein" times and high costs, limiting their accessibility. Bispecific therapies are more ...

The off-the-shelf CAR-T cell therapy specialist disclosed the changes alongside delays to two milestones. California-based Allogene has three clinical programs. Tuesday, the company disclosed ...

Tandem-target CAR-T produced a response in all participants with relapsed or refractory mantle cell lymphoma in a phase 1/2 study. Patients received their CAR-T within 8 to 12 days of lymphodepletion.